PER 1.23% 8.0¢ percheron therapeutics limited

CD49d promotes disease progression in chronic lymphocytic leukemia, page-7

  1. 4,103 Posts.
    lightbulb Created with Sketch. 1864
    @Shyam 1996
    Hi
    yes i know DMD is our priority, this is not my point, i have been in ANP long term and have always maintained they have always kicked the goals pipeline wise and the only reason i am still around i believe in the pipeline, but IMHO they have never put any emphasis on ROI for its investors,

    There is more to running the company than pipeline focus, it is a two headed coin they have shareholders as well, if a partnership does not come to fruition, Raising will not be a problem AT WHAT COST

    i will be left asking why has this not been promoted more to high net worth investors over our milestones achieved throughout the year

    The above is a classic example of missed opportunity to promote what i see as major news and price sensitive information

    WHY

    Look at the promotion for all we have achieved over this last twelve months it borders on a joke

    Will catch up further on this subject later
 
watchlist Created with Sketch. Add PER (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.